GlobalData on MSN15d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatmentMediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
Hosted on MSN17d
Lilly signs licensing deal with Mediar for IPF drugMediar said it expects to initiate a Phase 2 study in the first half of 2025. After the study is completed, Lilly (NYSE:LLY) will have the right to lead further development and commercialization ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback